Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.

IF 3 4区 医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-12-01 Epub Date: 2024-10-01 DOI:10.1080/14796694.2024.2406597
Claire N Harrison, Sonia Fox, Rebecca Boucher, Mary Frances McMullin, Adam J Mead
{"title":"Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.","authors":"Claire N Harrison, Sonia Fox, Rebecca Boucher, Mary Frances McMullin, Adam J Mead","doi":"10.1080/14796694.2024.2406597","DOIUrl":null,"url":null,"abstract":"<p><p>[Figure: see text].</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3365-3376"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789465/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2406597","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

[Figure: see text].

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MAJIC-PV研究中用Ruxolitinib治疗血癌多发性红细胞症:通俗易懂的摘要。
这是一篇文章的摘要,介绍了 MAJIC-PV 研究的主要结果。这项研究探讨了使用抗癌药物鲁索利替尼治疗一种名为 "多发性红细胞增多症 "的血癌。多发性红细胞症患者体内的红细胞过多。研究人员想知道,与现有的最佳疗法相比,Ruxolitinib 的疗效如何,以治疗有可能导致心脏病发作或中风的血栓形成风险的红细胞增多症患者。具体来说,这项研究的对象是已经服用过化疗药物羟基卡巴酰胺(又称羟基脲)治疗红细胞增多症的患者,但这种药物对他们不起作用,或者给他们带来了无法忍受的副作用:在这项研究中,研究人员将 180 名患有多血细胞增多症的成人患者分为两组,其中 93 人每天服用两次 ruxolitinib,87 人服用现有的最佳疗法。43%服用ruxolitinib的患者和26%接受最佳疗法的患者在治疗1年内血细胞计数和脾脏大小正常。84%的服用鲁索利替尼者和75%的接受最佳疗法者至少存活了3年,其多血细胞瘤没有发展成更晚期的血癌。最常见的副作用是消化系统(胃和肠道)疾病、血管疾病和感染。结果说明了什么?与采用现有最佳疗法治疗多发性红细胞增多症的患者相比,服用 Ruxolitinib 的患者更有可能在治疗后 1 年内血细胞计数和脾脏大小恢复正常,并且更有可能在多发性红细胞增多症未发展为更晚期血癌的情况下延长寿命。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
期刊最新文献
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer. Asciminib in the treatment of chronic myeloid leukemia in chronic phase. Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1